SOPHiA GENETICS Shareholders Approve Leadership Transition: Ross Muken to Become CEO, Co-Founder Jurgi Camblong Elected Executive Chairman
核心洞察
SOPHiA GENETICS (搜索) shareholders approved all AGM proposals, including the election of co-founder Dr. Jurgi Camblong as Executive Chairman with 99.79% of votes.
Ross Muken was elected to the Board and will assume the CEO role effective July 1, 2026, receiving 99.88% shareholder support.
The leadership transition follows a multi-year succession process and introduces a Lead Independent Director role with robust governance arrangements.
SOPHiA GENETICS (搜索) (Nasdaq: SOPH), a global leader in AI-driven precision medicine, has secured shareholder approval for a carefully orchestrated leadership transition that will see President Ross Muken ascend to Chief Executive Officer and co-founder Dr. Jurgi Camblong move to Executive Chairman of the Board. The decisions were ratified at the company's 2026 Annual General Meeting (AGM) held on June 18, 2026, with near-unanimous support from shareholders.
The transition, first announced in January 2026, represents the culmination of what outgoing Chairman Troy Cox described as "a disciplined, multi-year process" undertaken by the Board. Ross Muken will formally assume the CEO role on July 1, 2026.
Shareholder Mandate and Governance Overhaul
Shareholders delivered overwhelming endorsements for the new leadership slate. Dr. Jurgi Camblong was elected as Executive Chairman with 99.79% of votes cast, while Ross Muken secured his first Board seat with 99.88% support. All other directors standing for re-election—including Troy Cox, Tomer Berkovitz, Jean-Michel Cosséry, Kathy Hibbs, Didier Hirsch, and Vincent Ossipow—were returned to the Board for one-year terms expiring at the 2027 AGM.
In conjunction with Dr. Camblong's election as Executive Chairman, the Board introduced a Lead Independent Director role that will rotate annually among the chairs of its independent Board committees. The Board will also hold standing executive sessions of independent directors at each meeting. These measures, combined with an independent majority on the Board and fully independent committees, establish what the company characterizes as "a clear, robust governance framework for its next chapter."
Ross Muken's Path to CEO
Muken joined SOPHiA GENETICS (搜索) in February 2021 and has held successive executive roles: first as Chief Financial Officer, then as CFO and Chief Operating Officer from March 2023, and most recently as company President since November 2024. His more than 20 years of experience spans life sciences, health technology, medical devices, and pharma services, including prior roles as CFO and COO of Click Therapeutics (搜索) and senior positions at Evercore/ISI Group, Deutsche Bank Securities, and Thomas Weisel Partners.
"I am deeply honored by Jurgi and the Board's confidence in me to lead SOPHiA GENETICS (搜索) at this important moment," Muken said. "Jurgi has built a truly exceptional company with a clear mission, a differentiated platform, and a passionate team dedicated to improving patient outcomes. I am excited to build on that foundation, accelerate our commercial momentum, and continue delivering value for patients, customers, and shareholders alike."
Camblong's Founder Legacy
Dr. Camblong co-founded SOPHiA GENETICS (搜索) in 2011 and has served as CEO since the company's inception, guiding its trajectory from a pioneering Swiss startup to a publicly listed global enterprise. As Executive Chairman, he will continue as a full-time executive, concentrating on technology innovation and long-term strategic direction.
"Co-founding SOPHiA GENETICS and serving as CEO over the past 15 years has been one of the greatest privileges of my professional life," Camblong said. "What makes me proud is not only how far we have come, but the extraordinary people, partners, and customers who have helped shape our mission along the way."
Troy Cox's Chairmanship Legacy
Troy Cox, who joined the Board in July 2019 and became Chairman in March 2020, presided over a transformative period for the company. Under his chairmanship, SOPHiA GENETICS (搜索) completed its Initial Public Offering on Nasdaq in 2021, scaled its operations globally, expanded its installed network to nearly 1,000 healthcare institutions across more than 75 countries, and surpassed 2 million genomic profiles analyzed on the SOPHiA DDM platform. Cox, who previously served as CEO of Foundation Medicine and led that company through its acquisition by Roche in 2018, has been nominated for re-election as a non-executive Board member.
Additional AGM Outcomes
Beyond the leadership elections, shareholders approved the maximum aggregate compensation for the Board and Executive Committee, an amendment to Article 4b of the Articles of Association concerning the annual share replenishment under the company's 2021 Equity Incentive Plan, and the 2025 financial results including the carry-forward of the net loss. PricewaterhouseCoopers SA was re-elected as external auditor, and PHC Notaires was re-elected as independent proxy.
The Compensation Committee was reconstituted with Kathy Hibbs, Jean-Michel Cosséry, and Vincent Ossipow, with Hibbs re-appointed as Chair.
Platform and Mission
SOPHiA GENETICS (搜索) positions itself as an AI-native healthcare technology company focused on transforming patient care through expanded access to data-driven medicine. Its core technology, the SOPHiA DDM platform, analyzes complex genomic and multimodal data to generate real-time, real-world insights for a global network of hospital, laboratory, and biopharma institutions.